¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"large cell carcinoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® embryonal carcinoma ÇÑ±Û ¹è¾Æ¾ÏÁ¾
¼³¸í   
  »ý½Ä¼¼Æ÷¿¡¼­ »ý±â´Â ¾ÏÁ¾ÀÇ Çϳª·Î ´ëºÎºÐ °íȯ¿¡¼­ ¹ß»ýÇÑ´Ù. µå¹°°Ô´Â Á¾°Ýµ¿¿¡¼­µµ ¹ß»ýÇÑ´Ù. 40~50´ëÀÇ ³²¼º¿¡°Ô ¸¹À¸³ª, À̺¸´Ù ³·Àº ¿¬·ÉÃþ¿¡¼­µµ ³ªÅ¸³­´Ù. À°¾ÈÀûÀ¸·Î´Â È¸¹é»öÀÇ ºÐ¿±À» º¸À̴ µ¢¾î¸®¸¦ Çü¼ºÇϸç, °íȯ ¾Ç¼º Á¾¾ç Áß ¿¹Èİ¡ ÁÁÀº ÆíÀÌ´Ù. Ä¡·áÀÇ ¿øÄ¢Àº °¡±ÞÀû ½Å¼ÓÇϰԠ¿ø¹ß¼Ò¸¦ ÀýÁ¦ÇÏ°í ¿¹»óµÇ´Â ÀüÀ̺´ÅÍ¿¡ ´ëÇÏ¿© ¹æ»ç¼± Á¶»ç¿ä¹ýÀ» ÇàÇØ¾ß ÇÑ´Ù. Å»ý¾ÏÁ¾ ¹æ»ç¼±¿ä¹ý¿¡ ´ëÇÏ¿© ¸Å¿ì °¨¼ö¼ºÀÌ ³ô±â ¶§¹®¿¡ º´±â°¡ ÃʱâÀ̸é 90% ÀÌ»óÀÇ Ä¡·á°¡ ±â´ëµÈ´Ù. ±×¸®°í È­Çпä¹ýÁ¦¿¡ ÀÇÇØ ±× Ä¡·á¼º°ú°¡ »ó½ÂÇϰí ÀÖ´Ù.
¿µ¹® carcinoma in situ ÇÑ±Û »óÇdz»¾ÏÁ¾
¼³¸í   
  ½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í Àִ Á¶Á÷À» »óÇǶó°í ÇÑ´Ù. ÀÌ »óÇÇÀÇ ¾Æ·¡¿¡´Â ´ë°³ »óÇǸ¦ ÁöÁöÇϰí Àִ Á¶Á÷ÀÇ À§¿¡ Á¸ÀçÇÑ´Ù. ±×¸®°í ÀÌ ÁöÁöÁ¶Á÷°ú »óÇÇ »çÀÌ¿¡´Â ±âÀú¸·À̶ó´Â ¸·ÀÌ À־ »óÇǿ͠ÁöÁöÁ¶Á÷À» ±¸ºÐÇØ ÁØ´Ù. ¾ÏÁ¾(carcinoma)¶õ »óÇÇÀÇ ¼¼Æ÷°¡ ¾Ç¼º º¯È­¸¦ ÇÏ¿© »ý±â´Â ¾ÏÀ» ¸»ÇÑ´Ù. Á¦ÀÚ¸®¾ÏÁ¾À̶õ ¾ÏÁ¾ÀÇ ÇÑ Á¾·ù·Î ¾ÏÁ¾ÀÌ ±âÀú¸·À» ¹þ¾î³ªÁö ¸øÇÏ°í »óÇdz» Áï, Á¦ÀÚ¸®¿¡ ¸Ó¹°·¯ Àִ °æ¿ì¸¦ ¸»ÇÑ´Ù.
¿µ¹® carcinoma ÇÑ±Û ¾ÏÁ¾
¼³¸í   
  ¾ÏÁ¾À̶õ »óÇǼ¼Æ÷(-½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í Àִ Á¶Á÷À» »óÇǶó°í Çϰí, »óÇǸ¦ ÀÌ·ç°í Àִ ¼¼Æ÷¸¦ »óÇǼ¼Æ÷¶ó°í ÇÑ´Ù)ÀÇ °úµµÇÑ Áõ½Ä¿¡ÀÇÇÑ ¾Ç¼ºÁ¾¾çÀ» À̸£´Â ¸»ÀÌ´Ù.
¿µ¹® muscle cell(=muscle fiber) ÇÑ±Û ±ÙÀ°¼¼Æ÷
¼³¸í   
  ±ÙÀ°Àº ¼öÀDZÙ(ÀǽĿ¡ ÀÇÇØ¼­ Á¶ÀýÀÌ °¡´ÉÇÑ ±ÙÀ°: ¿¹¸¦ µé¾î ´Ù¸®, ÆÈ, ¾ó±¼±ÙÀ° µî)°ú ºÒ¼öÀDZÙ(Àǽİú ¹«°üÇϰԠÁ¶ÀýÇÏÁö ¾Ê¾Æµµ ¿òÁ÷À̴ ±ÙÀ°: ¿¹¸¦ µé¾î ½ÉÀå±Ù, ¼ÒÈ­±â°ü¿¡ ºÐÆ÷Çϴ ±ÙÀ° µî)À¸·Î ³ª´©¾îÁö¸ç, ±ÙÀ°¼¼Æ÷ÀÇ ¸ð¾çÀº ´ÙÀ½°ú °°´Ù(¼öÀDZÙ, ºÒ¼öÀDZ٠¿Ü¿¡ ½ÉÀå¿¡ Àִ ½ÉÀå±ÙÀº ºÒ¼öÀDZٿ¡ ÇØ´çÇÏÁö¸¸ ±× ¸ð¾çÀº ¼öÀDZٰú °°¾Æ µû·Î ºÐ·ùÇÑ´Ù).
  
  ±ÙÀ°¼¼Æ÷
¿µ¹® white blood cell(WBC), leukocyte ÇÑ±Û ¹éÇ÷±¸
¼³¸í   
  Ç÷¾×³»¿¡ °ñ¼ö±¸°è¼¼Æ÷¿Í ¸²ÇÁ°è¼¼Æ÷, ´ÜÇÙ±¸°è¼¼Æ÷¸¦ ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ¹éÇ÷±¸ÀÇ Áõ°¡°¡ ÀÖÀ¸¸é ´ë°³ °¨¿°ÀÌ Àְųª, È¤Àº Å»¼öÇö»óÀÌ ÀÖÀ½À» ÀǹÌÇÑ´Ù. ¶ÇÇÑ Áö³ªÄ£ ¹éÇ÷±¸¼öÀÇ °¨¼Ò´Â ÀÎü³» ¸é¿ª±â´ÉÀÌ ¶³¾îÁ® ÀÖÀ½À» ÀǹÌÇϸç, ´Ù¸¥ Áúº´¿¡ ÀÇÇØ ³ªÅ¸³ª´Â ÀÌÂ÷ÀûÀΠÇö»óÀÌ ¾Æ´ÑÁö ²À Áø´ÜÀ» ¹Þ¾Æº¸¾Æ¾ß ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • islet cell carcinoma
    ¼¶¼¼Æ÷¾ÏÁ¾
  • non-small cell carcinoma
    ºñ¼Ò¼¼Æ÷¾ÏÁ¾
  • oat cell carcinoma
    ±Í¸®¼¼Æ÷¾ÏÁ¾
  • renal cell carcinoma
    ÄáÆÏ¼¼Æ÷¾ÏÁ¾, ½ÅÀå¼¼Æ÷¾ÏÁ¾
  • spindle cell carcinoma
    ¹æÃß¼¼Æ÷¾ÏÁ¾
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • squamous cell in situ carcinoma
    ÆíÆò¼¼Æ÷Á¦ÀÚ¸®¾ÏÁ¾
  • signet ring cell carcinoma
    ¹ÝÁö¼¼Æ÷¾ÏÁ¾
  • small cell carcinoma
    ¼Ò¼¼Æ÷¾ÏÁ¾
  • apocrine carcinoma
    ¾ÆÆ÷Å©¸°¾ÏÁ¾
  • adenocystic carcinoma
    »ù³¶¾ÏÁ¾, ¼±³¶¾ÏÁ¾
  • adenoid cystic carcinoma
    »ù³¶¾ÏÁ¾, ¼±³¶¾ÏÁ¾
  • adenoma-carcinoma sequence
    »ùÁ¾¾ÏÁ¾¿¬¼â, ¼±Á¾¾ÏÁ¾¿¬¼â
  • adnexal carcinoma
    ºÎ¼Ó±â°ü¾ÏÁ¾
  • anaplastic carcinoma
    ¿ªÇü¼º¾ÏÁ¾
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • papillary thyroid carcinoma
    À¯µÎ°©»ó»ù¾ÏÁ¾
  • tubular carcinoma
    °ü¾ÏÁ¾
  • sickle cell anemia
    ³´ÀûÇ÷±¸ºóÇ÷
  • cell
    ¼¼Æ÷
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • basal cell
    ¹Ù´Ú¼¼Æ÷, ±âÀú¼¼Æ÷
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • ethmoidal cell
    ¹úÁý»À¹úÁý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • signet ring cell carcinoma
    ¹ÝÁö¼¼Æ÷¾ÏÁ¾
  • small cell carcinoma
    ¼Ò¼¼Æ÷¾ÏÁ¾
  • spindle cell carcinoma
    ¹æÃß¼¼Æ÷¾ÏÁ¾
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
  • acinar carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • adenocystic carcinoma
    (¢¡adenoid cystic carcinoma) »ù³¶¾ÏÁ¾
  • adenoid cystic carcinoma
    »ù³¶¾ÏÁ¾
  • adenoma-carcinoma sequence
    »ùÁ¾¾ÏÁ¾¼ø¼­
  • adnexal carcinoma
    ºÎ¼Ó±â°ü¾ÏÁ¾
  • apocrine gland carcinoma
    ¾ÆÆ÷Å©¸°¶¡»ù¾ÏÁ¾
  • arsenical carcinoma
    ºñ¼Ò¾ÏÁ¾
  • bronchioloalveolar carcinoma
    ¼¼±â°üÁöÆóÆ÷¾ÏÁ¾, ¼¼±â°üÁö²Ê¸®¾ÏÁ¾
  • bronchogenic carcinoma
    ±â°üÁöÀ¯·¡¾ÏÁ¾
  • carcinoma
    ¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adenocystic carcinoma
    ¼±³¶Á¾¼º¾Ï
  • adenoid cystic carcinoma
    ¼±¾ç³¶¼º¾ÏÁ¾(àÍåÆÒ¥àõäßðþ)
  • adenoma-carcinoma sequence
    ¼±Á¾-¾ÏÁ¾ ¿¬¼â(àÍðþ-äßðþ ææáð)
  • adnexal carcinoma
    ºÎ¼Ó±â(ݾáÕÐï) ¾Ï
  • apocrine gland carcinoma
    ¾ÆÆ÷Å©¸°¼±(~ àÍ) ¾Ï(Á¾)(äß(ðþ))
  • arsenical carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ¾Ï(Á¾)
  • gastric carcinoma
    À§¾ÏÁ¾(êÖäßðþ)
  • glandular carcinoma
    ¼±¾ÏÁ¾(¼±¾ÏÁ¾).
  • hepatocellular carcinoma
    °£¼¼Æ÷¼º ¾Ï
  • hepatocellular carcinoma
    °£¼¼Æ÷¾ÏÁ¾(ÊÜá¬øàäßðþ)
  • pilomatrix carcinoma
    ¸ð¹ß±âÁú ¾Ï(Á¾)
  • postcricoid carcinoma
    ÈÄÀ±(»ó)¾ÏÁ¾
  • primary bronchogenic carcinoma
    ¿ø¹ß(¼º)±â°üÁö¾Ï
  • primary carcinoma
    ¿ø¹ß¾ÏÁ¾(ê«Û¡äßðþ)
  • primary cutaneous adenocystic carcinoma
    ¿ø¹ß¼º ÇǺΠ¼±³¶Á¾¼º¾Ï
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adenoid basal cell carcinoma
    ¼±»ó(àÍßÒ) ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • adenoid squamous cell carcinoma
    ¼±»ó ÆíÆò »óÇǼ¼Æ÷(àÍßÒ ø·øÁ ß¾ù«á¬øà) ¾Ï
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ±âÀú¼¼Æ÷¾Ï
  • basal cell carcinoma
    ±âÀú¼¼Æ÷¾Ï
  • basal cell carcinoma
    ±âÀú¼¼Æ÷¾ÏÁ¾ (¡­äßðþ)
  • basal cell carcinoma, of penis
    À½°æ ±âÀú¼¼Æ÷¾ÏÁ¾
  • basosquamous cell carcinoma
    ±âÀú ÆíÆò¼¼Æ÷ ¾Ï(Á¾)
  • carcinoma, spindle cell
    ¹æÃ߻󼼯÷ ¾ÏÁ¾
  • carcinoma,renal cell
    ½Å ¼¼Æ÷ (ãìá¬øà)
  • carcinoma,squamous cell
    ÆíÆò»óÇǾÏÁ¾(ø·øÁß¾ù«äßðþ)
  • cicatrizing basal cell carcinoma
    ÈäÅͼº ±âÀú¼¼Æ÷¾Ï
  • circumscribed basal cell carcinoma
    ±¹ÇѼº ±âÀú¼¼Æ÷¾Ï
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾Ï
  • cystic basal cell carcinoma
    ³¶Á¾¼º ±âÀú¼¼Æ÷¾Ï
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Dark cell [Norepinephrine cell]
    ¾îµÎ¿î¼¼Æ÷ [³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷(³ë¸£¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Supporting cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷(Á¦2Çü»ç±¸¼¼Æ÷)
  • Striated muscle cell
    °¡·Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] Ⱦ¹®±Ù¼¼Æ÷
  • Sensory epithelial cell
    °¨°¢»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] °¨°¢»óÇǼ¼Æ÷
  • Cortical endocrine cell
    °ÑÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ÇÇÁú³»ºÐºñ¼¼Æ÷
  • Nodal cell
    °áÀý¼¼Æ÷
    [¿¾ ¿ë¾î] °áÀý¼¼Æ÷
  • Granule cell
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³¼¼Æ÷
  • Granular lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
  • Granulosa lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
  • Myoepithelial cell
    ±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ±Ù»óÇǼ¼Æ÷
  • Myoid cell layer
    ±ÙÀ°¼¶À¯¸ð¼¼Æ÷Ãþ
    [¿¾ ¿ë¾î] ±Ù¼¶À¯¾Æ¼¼Æ÷Ãþ
  • Satellite cell of skeletal muscle
    ±ÙÀ°À§¼º¼¼Æ÷
    [¿¾ ¿ë¾î] ±ÙÀ§¼º¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell coat
    ¼¼Æ÷(á¬øà)²®Áú
  • cell cycle
    ¼¼Æ÷ÁÖ±â(á¬øàñÎÑ¢)
  • cell differentiation
    ¼¼Æ÷ºÐÈ­(á¬øàÝÂûù)
  • cell envelope
    ¼¼Æ÷(á¬øà)½Î°³
  • cell factor
    ¼¼Æ÷ÀÎÀÚ(á¬øàì×í­)
  • cell fractionation
    ¼¼Æ÷ºÐȹȭ(á¬øàÝÂüñûù)
  • cell-free amino acid incorporating system
    ¹«¼¼Æ÷(Ùíá¬øà) ¾Æ¹Ì³ë»ê ÆíÀÔ(øºìý)¾¾½ºÅÛ
  • cell-free extract
    ¹«¼¼Æ÷ÃßÃâ¹°(Ùíá¬øàõÎõóÚª)
  • cell-free protein synthesis
    ¹«¼¼Æ÷´Ü¹éÁúÇÕ¼º(Ùíá¬øàÓ±ÛÜòõùêà÷)
  • cell-free system
    ¹«¼¼Æ÷(Ùíá¬øà)½Ã½ºÅÛ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ(á¬øàë×ùê)
  • cell hybridization
    ¼¼Æ÷(á¬øà) Æ¢±âÇü¼º(û¡à÷)
  • cell line
    ¼¼Æ÷ÁÖ(á¬øàñ»)
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª(á¬øàØÚË¿Øóæ¹)
  • cell membrane
    ¼¼Æ÷¸· (á¬øàØ¯)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mucoepidermoid carcinoma
    Á¡¾×Ç¥ÇǾç¾ÏÁ¾
  • mucosal carcinoma
    Á¡¸·¾ÏÁ¾
  • pancreatic carcinoma
    ÃéÀå¾ÏÁ¾
  • undifferentiated carcinoma
    ¹ÌºÐÈ­¾ÏÁ¾
  • acinar cell
    Æ÷»ó¼¼Æ÷
  • air cell
    ÇԱ⵿
  • blast cell
    ¸ð¼¼Æ÷
  • blood cell
    Ç÷±¸
  • cell
    ¼¼Æ÷, ¹úÁý, ºÀ¼Ò, °ÇÀüÁö
  • chromaffin cell
    Å©·Òģȭ¼¼Æ÷
  • clear cell
    Åõ¸í ¼¼Æ÷
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷
  • daughter cell
    µþ¼¼Æ÷, ³¶¼¼Æ÷
  • dendrite cell
    ³ª¹«°¡Áö¼¼Æ÷, ¼ö»ó¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ALL Acute Lymphocytic Leukemia
  ÇüÅÂÇÐÀû ºÐ·ù
    L1; Small, Homogenous(...
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
LGL large granular leukocyte; large granular lymphocyte; Lown-Ganong-Levine [syndrome]
BC Bachelor of Surgery [Lat. Baccal-aureus Chirurgiae]; back care; bactericidal concentration; basal ce...
PC avoirdupois weight [Lat. pondus civile]; packed cells; paper chromatography; paracortex; parent cell...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DLBL Diffuse large B cell lymphoma
LCAL Large cell anaplastic lymphoma
LCL Large cell lymphoma
ALC anaplastic large cell
LUC large unstained cell
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • adenoid basal cell carcinoma
    ¼±»ó ±âÀú¼¼Æ÷¾Ï
  • adenosquamous cell carcinoma
    ¼± ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ¼± ¾Ï°ú ÆíÆò¼¼Æ÷ ¾ÏÀÌ È¥ÀçµÇ¾î ÀÖ´Â °Í. ÀÚ±Ã°æ ³»¸· »óÇÇÀÇ ±âÀú Ãþ¿¡ ÀÖ´Â ¿¹ºñ ¼¼Æ÷¿¡¼­ ¹ß»ý. ÀÌ´Â °°Àº º´±âÀÇ ÆíÆò¼¼Æ÷ ¾Ï°ú ºñ±³ÇÏ¿© ¿¹Èİ¡ ´õ ³ª»Ú´Ù.
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï
  • alveolar cell carcinoma
    ÆóÆ÷ ¼¼Æ÷ ¾ÏÁ¾
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º ±âÀú¼¼Æ÷ ¾Ï
  • basal cell carcinoma
    ±âÀú ¼¼Æ÷ ¾Ï, ±âÀú ¼¼Æ÷ ¾ÏÁ¾
    1. »óÇÇÀÇ ±âÀú ¼¼Æ÷¸¦ ´àÀº ±âº» ±¸Á¶¸¦ °¡Áö´Â »óÇÇ ¼¼Æ÷ ½Å»ý¹°. À̰ÍÀº »óÇÇ ¼¼Æ÷ÀÇ ±âÀú ¼¼Æ÷, ¸ð³¶À̳ª ÇÇÁö¼±ÀÇ ¿Ü¹æ ¼¼Æ÷, ƯÈ÷ ¾È¸éÀÇ °¡¿îµ¥ 1/3¿¡¼­ ¹ß»ýÇÑ´Ù. µå¹°°Ô ÀüÀ̵ÇÁö¸¸ ±¹¼ÒÀûÀ¸·Î ħ¹üÇÑ´Ù. ±¸°­ Á¡¸·¿¡¼­´Â ¹ß»ýÇÏÁö ¾Ê´Â´Ù. Çѱ¹ÀÎ ÇǺΠ¾Ç¼º Á¾¾ç Áß °¡Àå ¸¹Àº ÇüÀÌ´Ù. ÀüÀ̰¡ Àß ¾ÈµÇ¸ç Àç¹ßÀ²ÀÌ ÀûÀº Áß°£ ¾Ç¼ºµµÀÌ´Ù. ±¸°­ÀÇ ±âÀú ¼¼Æ÷ ¸ð¹Ý ÁõÈıº°ú °ü·ÃÀÌ ÀÖ´Ù. 2. Ç¥ÇÇ ±âÀúÃþÀÇ ¾Ç¼º Á¾¾ç.
  • columnar cell carcinoma
    ¿øÁÖ ¼¼Æ÷ ¾ÏÁ¾
  • fibrosing basal cell carcinoma
    ¼¶À¯¼º ±âÀú ¼¼Æ÷ ¾Ï
  • invasive squamous cell carcinoma
    ħÀÔ¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • morphealike basal cell carcinoma
    ¹Ý»ó °æÇÇÁõ °°Àº ±âÀú ¼¼Æ÷¾Ï
  • non-keratinized squamous cell carcinoma
    ºñ°¢È­¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • papillary squamous cell carcinoma
    À¯µÎ»ó ÆíÆò »óÇÇ ¼¼Æ÷¾Ï
  • prickle cell carcinoma
    ±Ø¼¼Æ÷ ¾Ï
  • renal cell carcinoma
    ½Å ¼¼Æ÷ ¾ÏÁ¾
  • transitional cell carcinoma
    ÀÌÇà ¼¼Æ÷ ¾ÏÁ¾
    ÁßÃþ »óÇÇ ¼¼Æ÷ÀÇ ÀÌÇàÇüÀ¸·ÎºÎÅÍ ¹ß»ýÇÏ´Â ¾Ç¼º Á¾¾ç.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
carcinoma, basal cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs.
(12 Dec 1998)
carcinoma, giant cell An epithelial neoplasm characterised by unusually large anaplastic cells. It is highly malignant with fulminant clinical course, bizarre histologic appearance and poor prognosis. It is most common in the lung and thyroid.
(12 Dec 1998)
carcinoma, islet cell A carcinoma of the islets of langerhans.
(12 Dec 1998)
carcinoma, merkel cell A carcinoma arising from merkel cells located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of merkel cell carcinoma, occurring generally in elderly patients.
(12 Dec 1998)
carcinoma, non-small-cell lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. They are dealt with collectively because of the shared properties of poor response to conventional chemotherapy and the potential for cure with surgical resection in a fraction of patients.
(12 Dec 1998)
carcinoma, renal cell Carcinoma of the renal parenchyma usually occurring in middle age or later and composed of tubular cells in varying arrangements. It was first described in 1826. Possible causal factors are environmental, hormonal, cellular, and genetic. Smoking is a definite risk factor and obesity is associated with increased risk. Renal cell carcinoma accounts for approximately 3% of adult cancer; the male-female ratio is 2:1. It is more common among urban residents than rural.
(12 Dec 1998)
carcinoma, signet ring cell A highly malignant, mucus-secreting tumour in which the mucus-secreting cells are anaplastic and appear rounded, with the nucleus displaced to one side by a globule of mucus in the cytoplasm.
(12 Dec 1998)
carcinoma, small cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterised by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. There are admixtures of small cell lung carcinoma with other types of lung cancer. Small cell carcinomas are distinguished by their distinctive biological features, response to chemotherapy and radiotherapy, and by their nearly universal tendency to develop overt or subclinical metastases, which frequently eliminates surgery in most patients.
(12 Dec 1998)
carcinoma, squamous cell A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present.
(12 Dec 1998)
carcinoma, transitional cell A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary bladder, ureters or renal pelves (especially if well differentiated), frequently papillary. Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically benign but being liable to recurrence.
(12 Dec 1998)
giant cell carcinoma <tumour> A malignant epithelial neoplasm characterised by unusually large anaplastic cells.
(05 Mar 2000)
giant cell carcinoma of thyroid gland A rapidly progressive undifferentiated carcinoma observed in the thyroid gland, characterised by numerous, unusually large, anaplastic cells derived from glandular epithelium of the thyroid gland.
(05 Mar 2000)
renal cell carcinoma <oncology, tumour> The most common form of kidney cancer which occurs when the cells lining the renal tubule undergo cancerous changes. There are approximately 18,000 new cases of renal cell carcinoma (hypernephroma) per year in the U.S. With about 8,000 deaths annually.
Smoking is considered a major risk factor. Kidney dialysis patients are at increased risk for the development of hypernephroma. Family history for renal cell carcinoma is also considered a risk factor.
Symptoms include haematuria, flank pain, abdominal pain, back pain, weight loss and abdominal swelling.
(27 Sep 1997)
clear cell carcinoma of kidney <radiology> Hypernephroma, renal cell carcinoma, arises from proximal collecting tubule, 10% bilateral adenocarcinoma types: papillary, alveolar, onchocytoma vascularity, 85% hypervascular (require pre-op embolization), 10% hypovascular (usually papillary type), 5% avascular associated with: tuberous sclerosis, von Hippel-Lindau syndrome see also: staging
(12 Dec 1998)
Hurthle cell carcinoma A neoplasm of the thyroid gland composed of polyhedral acidophilic cells, thought by some to be oncocytes; it may be benign or malignant, the behaviour of the latter depending on the general microscopic pattern, whether follicular, papillary, or undifferentiated.
See: Hurthle cell adenoma.
Synonym: Hurthle cell carcinoma.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell division
    ¼¼Æ÷ºÐ¿­
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell lysis
    ¼¼Æ÷¿ëÇØ
  • cell membrane
    ¼¼Æ÷¸·;¿øÇüÁú¸·;=CELL WALL
  • cell sorter
    ¼¼Æ÷ ºÐº°±â
  • cell therapy
    ¼¼Æ÷¿ä¹ý(¾çÀÇ °«³­»õ³¢ÀÇ ¼¼Æ÷¸¦ ÁÖÀÔÇϴ ȸÃá¹ý ('
  • cell wall
    ¼¼Æ÷º®
  • cell-mediated immunity
    ¼¼Æ÷(¸Å°³)¼º ¸é¿ª(¼¼Æ÷¸·¿¡ ºÎÂøÇÏ´Â Ç×üÀÇ Á߻꿡 ÀÇÇÑ
  • closed-cell
    µ¶¸³±âÆ÷ÀÇ;¹ÐÆó±âÆ÷ÀÇ(¼ÒÀç´Â ÇÃ¶ó½ºÆ½µî)
  • complementary cell
    º¸Á· ¼¼Æ÷
  • condemned cell (ward)
    »çÇü¼ö °¨¹æ
  • corticopontine cell
    ÇÇÁú±³¼¼Æ÷(´ë³ú ÇÇÁú¿¡ ÀÖÀ¸¸ç ½Ã°¢ ÀÚ±ØÀ» ³ú±³¿¡ º¸³¿)
  • death cell
    »çÇü¼ö °¨¹æ(µ¶¹æ)
  • dry cell
    °ÇÀüÁö
  • egg cell
    ³­¼¼Æ÷;³­ÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á